PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help


Alternate Names:  IDDM1; IDDM2
Alternate Symbols:  None
PharmGKB Accession Id: PA201


Cytogenetic Location: chr11 : p15.5 - p15.5
GP mRNA Boundary: chr11 : 2181009 - 2182439
GP Gene Boundary: chr11 : 2178009 - 2192439
Strand: minus


UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics
    Representation of anti-diabetic drugs repaglinide, nateglinide and sulfonylurea effects on insulin secretion in pancreatic cells.

External Pathways

Links to non-PharmGKB pathways.

  1. Arf6 trafficking events - (Pathway Interaction Database NCI-Nature Curated)
  2. FOXA1 transcription factor network - (Pathway Interaction Database NCI-Nature Curated)
  3. FOXA2 and FOXA3 transcription factor networks - (Pathway Interaction Database NCI-Nature Curated)
  4. Glucose Regulation of Insulin Secretion - (Reactome via Pathway Interaction Database)
  5. growth hormone signaling pathway - (BioCarta via Pathway Interaction Database)
  6. Insulin Pathway - (Pathway Interaction Database NCI-Nature Curated)
  7. Insulin receptor recycling - (Reactome via Pathway Interaction Database)
  8. insulin signaling pathway - (BioCarta via Pathway Interaction Database)
  9. Insulin Synthesis and Secretion - (Reactome via Pathway Interaction Database)
  10. Insulin-mediated glucose transport - (Pathway Interaction Database NCI-Nature Curated)
  11. IRS activation - (Reactome via Pathway Interaction Database)
  12. mTOR signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  13. SHC activation - (Reactome via Pathway Interaction Database)
  14. Signal attenuation - (Reactome via Pathway Interaction Database)
  15. Signaling by Insulin receptor - (Reactome via Pathway Interaction Database)
  16. Signaling events mediated by PTP1B - (Pathway Interaction Database NCI-Nature Curated)

Publications related to INS: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. American journal of human genetics. 2012. Saxena Richa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors. Journal of cellular physiology. 2002. Zhou Jie, et al. PubMed


Comparative Toxicogenomics Database:
HumanCyc Gene:

Common Searches